Marks P A, Rifkind R A
DeWitt Wallace Research Laboratories, Memorial Sloan-Kettering Cancer Center.
Rinsho Ketsueki. 1990 Apr;31(4):401-8.
Conceptually, the use of cytodifferentiation agents to suppress oncogenicity may prove most effective in long-term continuous treatment of patients whose tumors display some inherent expression of differentiated characteristics. This is the case in many pre-malignant lesions. The difficulty in evaluating the therapeutic role for HMBA is often times in separating in vivo cytotoxic from cytodifferentiation effects. Only with further studies will it be determined whether these and other cytodifferentiation agents are therapeutically useful and whether study of the mechanism faction of these agents provides additional understanding of the processes of cellular transformation and differentiation with which they interact.
从概念上讲，使用细胞分化剂来抑制致癌性，对于肿瘤表现出某些分化特征固有表达的患者进行长期持续治疗可能最为有效。许多癌前病变就是这种情况。评估六亚甲基双乙酰胺（HMBA）治疗作用的困难往往在于区分体内细胞毒性和细胞分化作用。只有通过进一步研究，才能确定这些以及其他细胞分化剂是否具有治疗作用，以及对这些药物作用机制的研究是否能增进我们对它们所相互作用的细胞转化和分化过程的理解。
